The Drugs Don't Work By Russell Clark of the Capital Flows and Asset Markets substack This week’s Economist has a leader, criticizing America’s...
The European Medicines Agency’s human medicines committee (CHMP) recommended against conditional authorization for Mirati’s KRAS G12C inhibitor Krazati...
Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product...
Treating heart disease and preventing coronary deaths have always been high priorities… The post CardiolRx study demonstrates ‘protective effects’...
West London may not have been an obvious choice for a growing biotech company, but Avacta Therapeutics might be on to something by moving away from...
Geovax Labs Inc (NASDAQ: GOVX) is a highly volatile stock that spent most of its history on the OTC where we reported on it many times...
It can be hard to wrap your head around the number of… The post A medical play developing CBD-based treatments for cardiovascular diseases appeared first...
Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug...
Nascent Biotech Inc (OTCMKTS: NBIO) is making a steady run northbound off its base at a nickel and saw some of its biggest gains while the...
Revive Therapeutics’ brass recently provided an update on Phase 3 of its clinical trial for Bucillamine. Bucillamine is a medicine designed to treat...
Diversifying a portfolio is often cited as a safe investing strategy, but it is also the game plan adopted by Sorrento Therapeutics (SRNE). This varied approach...
'Orphan drugs' with high price points are being tested as treatments for COVID-19. There's a better way to spur low-cost innovation for new drugs.
Inovio Pharmaceuticals: COVID-19 Vaccine Not the Only Path to Success